2019
Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough?
Gubitosi‐Klug R, Bebu I, White NH, Malone J, Miller R, Lorenzi GM, Hainsworth DP, Trapani VR, Lachin JM, Tamborlane WV, Group* F. Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough? Pediatric Diabetes 2019, 20: 743-749. PMID: 31206973, PMCID: PMC7217664, DOI: 10.1111/pedi.12877.Peer-Reviewed Original ResearchConceptsYears of ageType 1 diabetesDiabetic retinopathyEye examEarly Treatment Diabetic Retinopathy Study (ETDRS) scaleMild non-proliferative diabetic retinopathyDiabetic Retinopathy Study scaleNon-proliferative diabetic retinopathyDiabetic retinopathy assessmentDiabetic retinopathy statusBaseline glycated hemoglobinClinical trial evidenceSignificant macular edemaProliferative diabetic retinopathyStandardized clinical trialsDiabetic retinopathy examinationsRetinopathy assessmentRetinopathy statusBaseline characteristicsComplications TrialMacular edemaCase seriesDiabetes controlIncident casesTrial evidenceRisk Factors for Kidney Disease in Type 1 Diabetes
Perkins BA, Bebu I, de Boer IH, Molitch M, Tamborlane W, Lorenzi G, Herman W, White NH, Pop-Busui R, Paterson AD, Orchard T, Cowie C, Lachin JM, Group O. Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care 2019, 42: dc182062. PMID: 30833370, PMCID: PMC6489116, DOI: 10.2337/dc18-2062.Peer-Reviewed Original ResearchConceptsHigher systolic blood pressureHigher mean triglyceridesSystolic blood pressureRisk factorsKidney diseaseBlood pressureIncident macroalbuminuriaMean triglyceridesMultivariable Cox proportional hazards modelsGlomerular filtration rate lossCox proportional hazards modelComplications Trial (DCCT) cohortNonglycemic risk factorsModifiable risk factorsFrequency of screeningAssociation of baselineType 1 diabetesProportional hazards modelGlycemic exposureTrial cohortDiabetes controlMale sexHazards modelClinical strategiesAdvanced stage
2018
Persistence of abnormalities in white matter in children with type 1 diabetes
Fox LA, Hershey T, Mauras N, Arbeláez AM, Tamborlane WV, Buckingham B, Tsalikian E, Englert K, Raman M, Jo B, Shen H, Reiss A, Mazaika P, for the Diabetes Research in Children Network (DirecNet). Persistence of abnormalities in white matter in children with type 1 diabetes. Diabetologia 2018, 61: 1538-1547. PMID: 29654376, PMCID: PMC5991628, DOI: 10.1007/s00125-018-4610-6.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkersBlood GlucoseCase-Control StudiesChildChild DevelopmentChild, PreschoolCognitive DysfunctionDiabetes Mellitus, Type 1Diffusion Tensor ImagingFemaleGlycated HemoglobinHumansLeukoencephalopathiesLongitudinal StudiesMagnetic Resonance ImagingMalePrognosisRisk FactorsTime FactorsUnited StatesConceptsType 1 diabetesNon-diabetic childrenWhite matter microstructureWhite matterAltered white matter developmentContinuous glucose monitoring (CGM) profilesFractional anisotropyConclusions/interpretationThese resultsPersistence of abnormalitiesLongitudinal observational studyWhite matter growthYoung childrenWhite matter developmentMild cognitive deficitsHigher fractional anisotropyDiabetes groupClinical centersMethodsOne hundredObservational studyDiabetesInterpretationThese resultsCognitive deficitsHyperglycaemiaDiabetes researchAdverse effects
2017
Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin
Tamborlane WV, Pfeiffer KM, Brod M, Nikolajsen A, Sandberg A, Peters AL, Van Name M. Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin. Current Medical Research And Opinion 2017, 33: 639-645. PMID: 28008782, DOI: 10.1080/03007995.2016.1275937.Peer-Reviewed Original ResearchConceptsBolus insulinDose timingBolus insulin therapyPrevious weekType 2 diabetesExperiences of peopleInsulin therapyTreatment optionsDiabetes educationWeb-based surveyType 1DiabetesMajority of respondentsInsulinSelf-report surveyGeneralizability of findingsT2DT1DMealWeeksHypoglycemiaRespondentsTherapyBolusPotential bias
2014
Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry
Nambam B, DuBose SN, Nathan BM, Beck RW, Maahs DM, Wadwa RP, Tamborlane WV, Foster NC, Miller KM, Haller MJ, Network F. Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry. Pediatric Diabetes 2014, 17: 15-20. PMID: 25330905, DOI: 10.1111/pedi.12231.Peer-Reviewed Original ResearchConceptsType 1 diabetesT1D Exchange Clinic RegistryElevated blood pressureBlood pressureClinic registryACE-I therapyReceptor blocker therapyGoal blood pressureDiagnosis of hypertensionPediatric diabetes clinicBlocker therapyBP goalHypertensive childrenUndertreated hypertensionARB therapyAggressive managementCardiovascular riskDiabetes clinicHigher BMIMedical recordsHypertensionReceptor inhibitorsDiabetesTherapyVisitsSafety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose
Sherr JL, Collazo M, Cengiz E, Michaud C, Carria L, Steffen AT, Weyman K, Zgorski M, Tichy E, Tamborlane WV, Weinzimer SA. Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose. Diabetes Care 2014, 37: 773-779. PMID: 24170766, PMCID: PMC3931387, DOI: 10.2337/dc13-1608.Peer-Reviewed Original ResearchConceptsBlood β-hydroxybutyrate levelsΒ-hydroxybutyrate levelsBasal insulinBlood glucose levelsBasal insulin infusionGlucose levelsBlood glucoseInsulin infusionMorning blood glucose levelsType 1 diabetic subjectsUsual basal ratesBasal rateLow glucose levelsSignificant ketonemiaDiabetic ketoacidosisDiabetic subjectsControl nightSensor-augmented pump systemGlucose valuesType 1Experimental nightInsulinLow glucoseNext morningInfusion
2013
Faster In and Faster Out: Accelerating Insulin Absorption and Action by Insulin Infusion Site Warming
Cengiz E, Weinzimer SA, Sherr JL, Tichy EM, Carria L, Cappiello D, Steffen A, Tamborlane WV. Faster In and Faster Out: Accelerating Insulin Absorption and Action by Insulin Infusion Site Warming. Diabetes Technology & Therapeutics 2013, 16: 20-25. PMID: 24367934, PMCID: PMC3887414, DOI: 10.1089/dia.2013.0187.Peer-Reviewed Original ResearchEffectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes
Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Tamborlane WV, . Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes. Diabetes Care 2013, 36: 4030-4035. PMID: 24130350, PMCID: PMC3836135, DOI: 10.2337/dc13-1074.Peer-Reviewed Original ResearchConceptsUsual care groupC-peptide concentrationsType 1 diabetesΒ-cell functionHybrid closed-loop controlSAP therapyPump therapyContinuous glucose monitorNew-onset type 1 diabetesPeak C-peptide concentrationMixed-meal tolerance testSensor-augmented pump therapyEarly intensive therapyΒ-cell preservationUsual care participantsDays of diagnosisC-peptide areaMultiple daily injectionsInsulin pump therapyDays/weekMean glucose concentrationMedian durationIntensive therapyPrimary outcomeDaily injectionsReduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes
Sherr JL, Cengiz E, Palerm CC, Clark B, Kurtz N, Roy A, Carria L, Cantwell M, Tamborlane WV, Weinzimer SA. Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes. Diabetes Care 2013, 36: 2909-2914. PMID: 23757427, PMCID: PMC3781513, DOI: 10.2337/dc13-0010.Peer-Reviewed Original ResearchConceptsNocturnal hypoglycemiaType 1 diabetesAfternoon exerciseInsulin deliveryAntecedent exerciseTarget blood glucose rangeCL insulin deliveryClosed-loop insulin deliveryLoop insulin deliveryTarget rangeBlood glucose levelsBlood glucose rangeMaximum heart rateCL controlBrisk treadmillReduced hypoglycemiaSedentary dayExercise dayPercentage of timeGlucose levelsHeart rateGlucose valuesType 1Random orderStudy period
2012
The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence
Ruedy KJ, Tamborlane WV, for the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence. Journal Of Cardiovascular Translational Research 2012, 5: 380-387. PMID: 22538483, DOI: 10.1007/s12265-012-9364-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Equipment DesignEvidence-Based MedicineGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsMulticenter Studies as TopicPatient SatisfactionPredictive Value of TestsRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsContinuous glucose monitorRandomized trialsT1D managementMulticenter Randomized TrialType 1 diabetesStandard glucose monitoringPrimary studiesComplications TrialSevere hypoglycemiaHemoglobin levelsDiabetes controlBiochemical hypoglycemiaCGM usePatientsGlucose monitoringAccumulated evidenceSecondary studiesReduced exposureTrialsA1CHypoglycemiaGlucose monitorSubjectsDCCTDiabetesThe Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin. Diabetes Care 2012, 35: 690-692. PMID: 22374642, PMCID: PMC3308292, DOI: 10.2337/dc11-0732.Peer-Reviewed Original ResearchConceptsType 1 diabetesDetemir insulinInsulin analoguesInsulin pharmacodynamicsRapid-acting insulin analoguesRapid-acting insulinTime-action profileEuglycemic glucose clampCommon regimenRandomized studyDaily injectionsUnits/Glucose clampInsulin actionSame syringePharmacodynamicsAspartInsulinDiabetesRandom orderAdverse effectsSeparate injectionsAction studiesInjectionMixed injectionAchievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function
Sherr J, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B, White NH, Arbelaez AM, Beck RW, Kollman C, Ruedy K, . Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual β-Cell Function. Diabetes Care 2012, 35: 817-820. PMID: 22323414, PMCID: PMC3308298, DOI: 10.2337/dc11-2190.Peer-Reviewed Original ResearchConceptsResidual β-cell functionΒ-cell functionSensor glucose levelsLower glucose variabilityType 1 diabetesGlucose levelsContinuous glucose monitoringT1D participantsGlucose variabilityMean sensor glucose levelPeak C-peptide levelsMixed meal tolerance testTarget A1C levelsC-peptide levelsLong-term T1DShort-term groupNondiabetic groupT1D groupA1c levelsT1D patientsLess hyperglycemiaNondiabetic individualsTolerance testInsulin treatmentHypoglycemia
2011
Long-term Results of an Obesity Program in an Ethnically Diverse Pediatric Population
Savoye M, Nowicka P, Shaw M, Yu S, Dziura J, Chavent G, O'Malley G, Serrecchia JB, Tamborlane WV, Caprio S. Long-term Results of an Obesity Program in an Ethnically Diverse Pediatric Population. Pediatrics 2011, 127: 402-410. PMID: 21300674, PMCID: PMC3065145, DOI: 10.1542/peds.2010-0697.Peer-Reviewed Original ResearchConceptsControl groupLow-density lipoprotein cholesterolTotal body fat massIntensive lifestyle programIntensive lifestyle interventionHomeostasis model assessmentActive intervention phaseWeight management programBody fat massLong-term resultsBMI z-scorePercent body fatDiverse pediatric populationFamily-based programsLifestyle interventionLipoprotein cholesterolTotal cholesterolObese childrenObese populationPediatric populationInsulin resistanceObesity programLifestyle programFat massIntervention groupOptimal Sampling Intervals to Assess Long-Term Glycemic Control Using Continuous Glucose Monitoring
Xing D, Kollman C, Beck RW, Tamborlane WV, Laffel L, Buckingham BA, Wilson DM, Weinzimer S, Fiallo-Scharer R, Group K. Optimal Sampling Intervals to Assess Long-Term Glycemic Control Using Continuous Glucose Monitoring. Diabetes Technology & Therapeutics 2011, 13: 351-358. PMID: 21299401, PMCID: PMC6468940, DOI: 10.1089/dia.2010.0156.Peer-Reviewed Original Research
2006
The Effects of Aerobic Exercise on Glucose and Counterregulatory Hormone Concentrations in Children With Type 1 Diabetes
Tansey MJ, Tsalikian E, Beck RW, Mauras N, Buckingham BA, Weinzimer SA, Janz KF, Kollman C, Xing D, Ruedy KJ, Steffes MW, Borland TM, Singh RJ, Tamborlane WV. The Effects of Aerobic Exercise on Glucose and Counterregulatory Hormone Concentrations in Children With Type 1 Diabetes. Diabetes Care 2006, 29: 20-25. PMID: 16373890, PMCID: PMC2396943, DOI: 10.2337/diacare.29.01.06.dc05-1192.Peer-Reviewed Original ResearchConceptsType 1 diabetesOral glucoseNorepinephrine concentrationsAerobic exerciseExercise sessionsGrowth hormoneAcute glucose-lowering effectGlucose concentrationAerobic exercise resultsLow glucoseIncidence of hypoglycemiaExercise-induced increaseGlucose-lowering effectCounterregulatory hormone concentrationsTarget heart rateTreatment of hypoglycemiaPlasma glucose concentrationDl risePlasma glucagonPlasma glucoseBlood glucoseVs. 6Baseline glucoseBaseline valuesHeart rate
2005
Single‐ and Multiple‐Dose Pharmacokinetics of Pioglitazone in Adolescents With Type 2 Diabetes
Christensen ML, Meibohm B, Capparelli EV, Velasquez‐Mieyer P, Burghen GA, Tamborlane WV. Single‐ and Multiple‐Dose Pharmacokinetics of Pioglitazone in Adolescents With Type 2 Diabetes. The Journal Of Clinical Pharmacology 2005, 45: 1137-1144. PMID: 16172178, DOI: 10.1177/0091270005279578.Peer-Reviewed Original ResearchConceptsMultiple-dose pharmacokineticsType 2 diabetesMultiple dosingDoses of pioglitazoneDaily dose administrationTotal serum concentrationsLast doseFirst doseSystemic exposureDose administrationSerum concentrationsBlood samplesPioglitazoneDose levelsActive metaboliteDosingDoseDiabetesPharmacokineticsAdolescentsHoursActive compoundsAdministrationDosesPredictors of Changes in Glucose Tolerance Status in Obese Youth
Weiss R, Taksali SE, Tamborlane WV, Burgert TS, Savoye M, Caprio S. Predictors of Changes in Glucose Tolerance Status in Obese Youth. Diabetes Care 2005, 28: 902-909. PMID: 15793193, DOI: 10.2337/diacare.28.4.902.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testImpaired glucose toleranceType 2 diabetesNormal glucose toleranceGlucose tolerance statusGlucose toleranceObese youthPredictors of changeObese childrenTolerance statusHigh riskGlucose tolerance testSevere obesityAfrican American descentTolerance testInsulin sensitivityC-peptideGlucose levelsDiabetesAnthropometric predictorsWeight changeAfrican American backgroundsPredictorsBaselineSubjects
1996
Co-existence of severe insulin resistance and hyperinsulinaemia in pre-adolescent obese children
Caprio S, Bronson M, Sherwin RS, Rife F, Tamborlane WV. Co-existence of severe insulin resistance and hyperinsulinaemia in pre-adolescent obese children. Diabetologia 1996, 39: 1489-1497. PMID: 8960831, DOI: 10.1007/s001250050603.Peer-Reviewed Original ResearchConceptsObese groupHyperglycaemic clampInsulin resistanceObese preadolescentsInsulin actionGlucose-stimulated insulin levelsHigher insulin infusion ratesNon-oxidative glucose metabolismGlucose uptakeDuration of obesityGroup of obeseNon-obese subjectsBeta-cell functionDevelopment of obesityEuglycaemic hyperinsulinaemic clampSevere insulin resistanceInsulin infusion rateCross-sectional analysisOnset of pubertyAbility of insulinSevere obesityObese adultsObese childrenObese subjectsInsulin levels
1995
Enhanced adrenomedullary response and increased susceptibility to neuroglycopenia: Mechanisms underlying the adverse effects of sugar ingestion in healthy children
Jones TW, Borg WP, Boulware SD, McCarthy G, Sherwin RS, Tamborlane WV. Enhanced adrenomedullary response and increased susceptibility to neuroglycopenia: Mechanisms underlying the adverse effects of sugar ingestion in healthy children. The Journal Of Pediatrics 1995, 126: 171-177. PMID: 7844661, DOI: 10.1016/s0022-3476(95)70541-4.Peer-Reviewed Original ResearchConceptsClinical Research CenterHealthy childrenPlasma glucose concentrationAdrenomedullary responseHypoglycemic clampSymptom scoresSugar ingestionStandard oral glucose loadOral glucose loadPlasma epinephrine levelsPlasma glucose levelsGlucose concentrationCognitive effectsSugar-free drinksP300 potentialEpinephrine levelsP300 auditoryGlucose loadInsulin levelsSymptomatic responsePlasma glucoseOral administrationGlucose levelsHormone concentrationsPhysiologic mechanisms
1993
Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. A comparison with insulin.
Kerr D, Tamborlane WV, Rife F, Sherwin RS. Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. A comparison with insulin. Journal Of Clinical Investigation 1993, 91: 141-147. PMID: 8423214, PMCID: PMC330007, DOI: 10.1172/jci116163.Peer-Reviewed Original ResearchConceptsRecombinant human insulin-like growth factor-1Insulin-like growth factor-1Growth factor-1Glucagon responseGlucose productionAbsent glucagon responsesPlasma glucose nadirsGrowth hormone responseInsulin-induced hypoglycemiaAwareness of hypoglycemiaGrowth hormone releaseFactor 1Hepatic glucose productionHuman insulin-like growth factor-1Recognition of hypoglycemiaSymptomatic awarenessNorepinephrine levelsCounterregulatory responsesHypoglycemic stimulusSympathetic activityGlucose nadirsGlucagon releaseBlood glucoseRebound increaseHormone release